// App-Quantinova.ai

TCT-71 : The NIREUS Randomized Trial: 1-Year Results of the BioNIR Ridaforolimus-Eluting Coronary Stent System (BioNIR) EUropean Angiography Study

Researchers

Presenter

  • Pieter Smits

Principal Investigators

  • Ori Ben-Yehuda

  • Ioanna Kosmidou

  • M Ozgu Ozan

  • Ovidiu Dressler

  • Michael Jonas

  • Shmuel Banai

  • Maciej Pruski Jr

  • Yoram Richter

  • Gregg Stone

Medical Centers

  • Cardiovascular Research Foundation, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States

  • Cardiovascular Research Foundation, New York, United States

  • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

  • Center for Cardiovascular Research and Development American Hear, Katowice, Poland

  • Cardiovascular Research Foundation and Columbia University Medical Center, New York, United States

  • Kaplan Medical Center, Raman Gan, Israel

  • Maasstad Ziekenhuis, Rotterdam, Netherlands

Locations

  • United States

  • Poland

  • Netherlands

  • Israel

Companies

  • Medinol Ltd.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Stable coronary artery disease

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • Ridaforolimus

  • ZoMaxx

  • Rapacan

  • BioNIR

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved